Autoimmune Disease Series--

Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is a chronic, progressive autoimmune disease that primarily affects peripheral joints. It is characterized by symmetric polyarthritis, which can lead to joint cartilage and bone destruction, joint deformities, and even involvement of multiple systemic organs such as the heart, lungs, and blood vessels. The pathogenesis of RA is complex, involving genetic factors (such as the HLA-DRB1 susceptibility gene), environmental factors (such as smoking and infections), and immune abnormalities. The activation of autoreactive T cells induces B cells to produce rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP). At the same time, synovial fibroblasts proliferate abnormally and secrete large amounts of pro-inflammatory cytokines (such as TNF-α, IL-6, IL-17) and matrix metalloproteinases (MMPs), ultimately leading to joint inflammation and bone erosion. The clinical manifestations include morning stiffness (lasting >30 minutes), symmetric joint swelling and pain (mainly in the small joints of the hands, wrists, and feet), rheumatoid nodules, and in the late stages, joint deformities (such as swan-neck deformity) and functional loss.

In recent years, RA drug development has focused on precisely targeting immune abnormality pathways, breaking through the limitations of traditional treatments (such as inadequate efficacy of methotrexate or resistance to biologics).

• IL-23/IL-17 axis-targeted drugs have become a hot topic. IL-23 activates Th17 cells to promote IL-17 secretion, which directly induces joint inflammation. In 2023, Eli Lilly's mirikizumab (anti-IL-23p19 monoclonal antibody) showed in Phase III trials that for patients with inadequate response to methotrexate, the combination treatment significantly outperformed placebo in terms of ACR50. Novartis' secukinumab (anti-IL-17A monoclonal antibody), although outstanding in psoriasis, showed in its RA extension studies (such as MEASURE 2) that it still had a 30%-40% ACR20 response rate in patients with TNF inhibitor resistance, indicating that IL-17 targeting is effective in specific subgroups.
• New-generation JAK inhibitors have optimized efficacy and safety. The selective JAK1 inhibitor upadacitinib was approved by the FDA in 2022. It has higher selectivity for JAK1 compared to JAK2/3, reducing the risk of hematologic side effects such as anemia compared to non-selective JAK inhibitors (such as tofacitinib). Phase III data showed that when used as monotherapy or in combination with methotrexate, the ACR50 response rate reached 48% at 12 weeks (vs. 28% for placebo).
• Complement system-targeted drugs are emerging. Overactivation of the complement system (especially the C5a-C5aR1 pathway) can recruit neutrophils and exacerbate synovial inflammation. ChemoCentryx's avacopan (anti-C5aR1 inhibitor), which has been approved for ANCA-associated vasculitis, showed in its RA Phase II trial (CCX140-202) that when combined with methotrexate, it led to better improvement in DAS28-CRP (disease activity score) at 24 weeks compared to placebo. It is currently in Phase III validation.

Additionally, epigenetic regulatory drugs (such as HDAC inhibitors) and B cell costimulation blockers (such as anti-CD40L) are still in the early stages of development, but they provide new directions for individualized RA treatment. Overall, RA drugs are evolving from "broad-spectrum anti-inflammatory" to "precision targeting." In the future, it may be possible to achieve more precise patient stratification and treatment selection through biomarkers (such as IL-23 levels, JAK phosphorylation status).